Head-To-Head Analysis: ITOCHU CORP/ADR (ITOCY) versus Allergy Therapeutics (AGYTF)

Share on StockTwits

ITOCHU CORP/ADR (OTCMKTS:ITOCY) and Allergy Therapeutics (OTCMKTS:AGYTF) are both retail/wholesale companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Valuation and Earnings

This table compares ITOCHU CORP/ADR and Allergy Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ITOCHU CORP/ADR $51.87 billion 0.59 $3.77 billion $4.86 7.57
Allergy Therapeutics $92.06 million N/A -$10.14 million ($0.02) -9.40

ITOCHU CORP/ADR has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than ITOCHU CORP/ADR, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for ITOCHU CORP/ADR and Allergy Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ITOCHU CORP/ADR 0 0 0 0 N/A
Allergy Therapeutics 0 0 0 0 N/A

Volatility & Risk

ITOCHU CORP/ADR has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of ITOCHU CORP/ADR shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares ITOCHU CORP/ADR and Allergy Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ITOCHU CORP/ADR 3.70% 11.96% 4.11%
Allergy Therapeutics N/A N/A N/A

Dividends

ITOCHU CORP/ADR pays an annual dividend of $1.04 per share and has a dividend yield of 2.8%. Allergy Therapeutics does not pay a dividend. ITOCHU CORP/ADR pays out 21.4% of its earnings in the form of a dividend.

Summary

ITOCHU CORP/ADR beats Allergy Therapeutics on 9 of the 10 factors compared between the two stocks.

ITOCHU CORP/ADR Company Profile

ITOCHU Corporation engages in trading and importing/exporting various products worldwide. The company's Textile segment produces and sells textile raw materials, garment materials, textile products, apparel, and industrial materials; and focuses on import licenses for lifestyle brands, fashion accessories, and garments in various areas, such as luxury, casual, and sports. Its Machinery segment provides engineering, procurement and construction services; operates water and environmental, infrastructure, renewable energy, petrochemical, and IPP projects and plants; sells and leases aircraft and related equipment; sells textile machinery, auto parts, medical equipment, electronic systems, and construction machinery; and owns, operates, and leases ships. The company's Metals & Minerals segment develops iron ore, coal, alumina, etc.; processes and trades in steel products; trades in iron ore, coal, aluminum, uranium, and non-ferrous products; and engages in steel recycling business. Its Energy & Chemicals segment trades in crude oil, petroleum products, LPG, LNG, natural gas, and electricity, as well as basic pharmaceutical products, sulfur, fertilizers, synthetic resins, household goods, fine chemicals, electronic materials, etc. The company's Food segment produces, distributes, and retails food products. Its General Products & Realty segment is involved in the wood products and building materials, pulp, paper, hygiene, natural rubber, tire, and logistics businesses; and real estate management and development, housing and renovation, etc. The company's ICT & Financial Business segment offers information technology solutions, Internet related services, venture capital services, mobile telephone equipment and services, broadcasting and communications, entertainment and content services, outsourcing services for healthcare and preventive medicine, financial services, and insurance brokerage services. The company was founded in 1858 and is headquartered in Tokyo, Japan.

Allergy Therapeutics Company Profile

Allergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen. The company also provides Acarovac Plus, a novel microcrystalline tyrosine adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). In addition, it develops products based on synbiotics that are Kallergen Th and SynGut; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; Polyvac, a peanut vaccine; and G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Receive News & Ratings for ITOCHU CORP/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITOCHU CORP/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Trollcoin  24 Hour Trading Volume Tops $143.00
Trollcoin 24 Hour Trading Volume Tops $143.00
Moss Coin Market Cap Tops $15.97 Million
Moss Coin Market Cap Tops $15.97 Million
Investors Buy Shares of Colgate-Palmolive  on Weakness
Investors Buy Shares of Colgate-Palmolive on Weakness
Traders Buy Shares of Cardinal Health  on Weakness
Traders Buy Shares of Cardinal Health on Weakness
Pecunio Tops 24 Hour Trading Volume of $340.00
Pecunio Tops 24 Hour Trading Volume of $340.00
Hashgard  Market Cap Reaches $2.08 Million
Hashgard Market Cap Reaches $2.08 Million


Leave a Reply

 
© 2006-2019 Zolmax.